Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Zhongxiang Wang
Observed names:
Z. Wang,
ZhongXiang Wang
Institutions:
The University of Western Australia,
First Affiliated Hospital of Wenzhou Medical University
Observed institutions:
The University of Western Australia,
First Affiliated Hospital of Wenzhou Medical University,
Peking University Cancer Hospital,
Shandong Tumor Hospital,
Second Affiliated Hospital of Zhejiang University,
Zhejiang University
show all 6
ORCID:
0000-0002-3468-6675
Observed ORCID:
0000-0002-3468-6675
OpenAlex ID:
A5070976293
OA04.03 A Randomized Phase 3 Study of Camrelizumab plus Chemotherapy as 1st Line Therapy for Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
2019
·
C. Zhou
, G. Chen
, et al.
·
Journal of Thoracic Oncology
·
31
PDF
Eicosapentaenoic acid supplementation modulates the osteoblast/osteoclast balance in inflammatory environments and protects against estrogen deficiency-induced bone loss in mice
2023
·
Zhongxiang Wang
, Jiaqi Wu
, et al.
·
Clinical Nutrition
·
26
PDF
Chaperone‐mediated autophagy protects the bone formation from excessive inflammation through PI3K/AKT/GSK3β /β‐catenin pathway
2024
·
Kai Hang
, YiBo Wang
, et al.
·
The FASEB Journal
·
14
SLAMF8 regulates osteogenesis and adipogenesis of bone marrow mesenchymal stem cells via S100A6/Wnt/β-catenin signaling pathway
2024
·
Yibo Wang
, Kai Hang
, et al.
·
Stem Cell Research & Therapy
·
12
PDF
P79.02 Updated OS and Time to Second Progression with First-Line Camrelizumab Plus Chemo vs Chemo for Advanced Non-Squamous NSCLC
2021
·
C. Zhou
, G. Chen
, et al.
·
Journal of Thoracic Oncology
·
8
PDF
36P Prevalence, clinical characteristics, and treatment outcomes of patients with BRAF-mutated advanced NSCLC in China: A real-world multi-center study
2023
·
B. Jia
, J. Zhao
, et al.
·
Journal of Thoracic Oncology
·
4
PDF
135P Camrelizumab plus chemotherapy as first-line therapy for NSCLC: A pooled analysis of two randomized phase III trials with extended follow-up
2022
·
C. Zhou
, G. Chen
, et al.
·
Immuno-Oncology Technology
·
2
PDF
A Systematic Review and Quality Assessment of Pharmacoeconomic Publications for China Compared to Internationally: Is the Quality of Evidence-base Sufficient for Health Technology Assessment?
2025
·
Zhixin Fan
, Xu Si
, et al.
·
International Journal of Health Policy and Management
·
1
Targeting the ‘Glucose-to-Fat’ Conversion in Bone Marrow to Ameliorate Bone Loss
2025
·
Kai Chen
, Zhongxiang Wang
, et al.
PDF
OA08.04 Plinabulin/Docetaxel vs. Docetaxel in 2L/3L NSCLC after Platinum Regimens (DUBLIN-3): A Phase 3 Randomized Controlled Trial
2024
·
T. Feinstein
, B. Han
, et al.
·
Journal of Thoracic Oncology
PDF
Show more works
View as search
Works count:
10
Citation count:
98
H-index:
5
I10-index:
4
Year
Topic
Type